Guideline: “Diagnosis and treatment of dementia and Mild cognitive impairment”

Supplementary material

Meta-analysis

REVIEW QUESTION 5. How effective are pre-, peri- and post-diagnostic counselling and support on outcomes for people living with dementia and their caregivers?

Outcomes of people with dementia

MMSE



ADCS-ADL



ADL



CDR-SB



NPI



Qol-AD

Study or Subgroup	Int Mean	Int SD	Int Total	Ctrl Mean	Ctrl SD	Ctrl Total	Weight	Mean Difference IV, Random, 95% CI
Koivisto 2016	-0.36	7.8336	84	1.22	10.0463	152	25.3%	-1.58 [-3.89, 0.73]
Phung 2013	-2.89	4.89	96	-2.84	2	103	43.4%	-0.05 [-1.10, 1.00]
Villars 2021	1.32	6.2348	98	-0.5	6.8967	97	31.3%	1.82 [-0.03, 3.67]
Total (95% CI)			**278**			**352**	**100.0%**	**0.15 [-1.46, 1.76]**

Heterogeneity: Tau² = 1.26; Chi² = 5.43, df = 2 (P = 0.07); I² = 63%
Test for overall effect: Z = 0.18 (P = 0.86)



REVIEW QUESTION 7a. What are the most effective methods of care planning, focusing upon improving outcomes for people with dementia and their carers?

Care coordination/management using a protocol/action plan (including training for caregivers) and monthly meetings



Care coordination/management using a protocol/action plan (including training for caregivers) and monthly meetings – ER admission



Care coordination/management using a protocol/action plan (including training for caregivers) and monthly meetings – institutionalization rate



Care coordination/management using a protocol/action plan (including training for caregivers) and monthly meetings – cognitive symptoms



Care coordination/management using a protocol/action plan (including training for caregivers) and monthly meetings – behavioural symptoms



Care coordination/management using a protocol/action plan (including training for caregivers) and monthly meetings – caregivers' depressive symptoms



Care coordination/management using a protocol/action plan (including training for caregivers) and monthly meetings – caregivers' satisfaction on services quality



Case management, follow-up every 2 months – NPI



Case management: combined, follow-up every month – cognitive symptoms



Case management: combined, follow-up every month – CSDD



Case management: combined, follow-up every month – quality of life of people with dementia



Case management: combined, follow-up every month – behavioural symptoms



Case management: combined, follow-up every month – institutionalization rate



Case management: combined, follow-up every 2 months – behavioural symptoms



Case management: follow-up visits at home – MMSE



Case management: follow-up at home or in clinics– behavioural symptoms



Case management: follow-up visits at home – caregivers' burden



Case management: follow-up visits at home – caregivers' quality of life



Case management: follow-up visits at home – institutionalization rate



REVIEW QUESTION 9. What effect does training for staff working with people living with dementia have upon the experiences of people living with dementia in their care?

BPSD Training – CMAI

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Davison 2007	-2.73	26.0975	46	0.59	39.4687	32	5.9%	-3.32 [-18.94, 12.30]
Deudon 2009	-6.52	16.8	174	-0.83	17.6	132	94.1%	-5.69 [-9.59, -1.79]
Total (95% CI)			**220**			**164**	**100.0%**	**-5.55 [-9.34, -1.76]**

Heterogeneity: Tau² = 0.00; Chi² = 0.08, df = 1 (P = 0.77); I² = 0%
Test for overall effect: Z = 2.87 (P = 0.004)



BPSD Training – CMAI-PA

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Deudon 2009	-0.15	1.4	174	-0.07	1.2	132	99.9%	-0.08 [-0.37, 0.21]
Visser 2008	3.81	7.3595	21	1.29	23.6313	32	0.1%	2.52 [-6.25, 11.29]
Total (95% CI)			**195**			**164**	**100.0%**	**-0.08 [-0.37, 0.21]**

Heterogeneity: Tau² = 0.00; Chi² = 0.34, df = 1 (P = 0.56); I² = 0%
Test for overall effect: Z = 0.52 (P = 0.60)



BPSD Training – CMAI-VA

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Deudon 2009	-0.07	0.7	174	0.09	0.6	132	77.7%	-0.16 [-0.31, -0.01]
Visser 2008	0.87	3.7786	21	-0.56	4.8261	32	22.3%	1.43 [-0.90, 3.76]
Total (95% CI)			**195**			**164**	**100.0%**	**0.19 [-1.10, 1.49]**

Heterogeneity: Tau² = 0.56; Chi² = 1.79, df = 1 (P = 0.18); I² = 44%
Test for overall effect: Z = 0.29 (P = 0.77)



Person-Centered – CMAI

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Chenoweth 2009	-10.3	12.719	98	7.4	9.4664	82	96.8%	-17.70 [-20.95, -14.45]
Chenoweth 2014	-18	75.3112	155	-1	80.4097	142	3.2%	-17.00 [-34.76, 0.76]
Total (95% CI)			**253**			**224**	**100.0%**	**-17.68 [-20.87, -14.48]**

Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 10.85 (P < 0.00001)



Care Mapping - CMAI

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Chenoweth 2009	-2.4	9.1121	109	7.4	9.4664	82	55.5%	-9.80 [-12.47, -7.13]
van de Ven 2013	1.57	25.116	73	0.52	27.1579	119	44.5%	1.05 [-6.50, 8.60]
Total (95% CI)			**182**			**201**	**100.0%**	**-4.97 [-15.54, 5.59]**

Heterogeneity: Tau² = 50.51; Chi² = 7.05, df = 1 (P = 0.008); I² = 86%
Test for overall effect: Z = 0.92 (P = 0.36)



Care Mapping – NPI

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Chenoweth 2009	0.8	7.1106	109	-1.6	7.3729	82	73.7%	2.40 [0.32, 4.48]
van de Ven 2013	0.93	11.0579	73	-2.15	13.276	119	26.3%	3.08 [-0.40, 6.56]
Total (95% CI)			**182**			**201**	**100.0%**	**2.58 [0.79, 4.36]**

Heterogeneity: Tau² = 0.00; Chi² = 0.11, df = 1 (P = 0.74); I² = 0%
Test for overall effect: Z = 2.83 (P = 0.005)



Care Mapping – quality of life of people with dementia

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI
Chenoweth 2009	1	2.2122	109	1.2	2.3666	82	50.8%	-0.09 [-0.37, 0.20]
van de Ven 2013	-2.07	25.2446	73	-2.2	27.4333	119	49.2%	0.00 [-0.29, 0.30]
Total (95% CI)			**182**			**201**	**100.0%**	**-0.04 [-0.25, 0.16]**

Heterogeneity: Tau² = 0.00; Chi² = 0.20, df = 1 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)



Reducing physical restraint frequency use

Study or Subgroup	Experimental Events	Total	Control Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
Huizing 2006	45	86	40	58	56.7%	0.76 [0.58, 0.99]
Pellfolk 2010	30	149	53	139	43.3%	0.53 [0.36, 0.77]
Total (95% CI)		**235**		**197**	**100.0%**	**0.65 [0.45, 0.94]**
Total events	75		93			

Heterogeneity: Tau² = 0.05; Chi² = 2.61, df = 1 (P = 0.11); I² = 62%
Test for overall effect: Z = 2.27 (P = 0.02)



REVIEW QUESTION 14b. How effective are carers' assessments in identifying the needs of informal carers of people living with dementia?

PSYCHOEDUCATIONAL INTERVENTIONS

ZBI



Stress



Depression



Self-efficacy



SKILL TRAINING

Caregiver burden



Depression


Experimental
Control
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
2.2.1 group CES-D
Gonzalez 2014 13.23 8.9 50 14.41 8.9 52 1.2% -1.18 [-4.64, 2.28]
Hepburn 2001 11.99 7.67 60 16.09 9.11 34 1.1% -4.10 [-7.73, -0.47]
Oken 2010 15.2 7.8 11 15.3 7.4 10 0.4% -0.10 [-6.60, 6.40]
Subtotal (95% CI) 121 96 2.7% -2.25 [-4.59, 0.08]
Heterogeneity: Tau² = 0.00; Chi² = 1.79, df = 2 (P = 0.41); I² = 0%
Test for overall effect: Z = 1.89 (P = 0.06)
2.2.2 group-ZDS
Zarit 1982 5.94 9.88 11 0.78 10.36 10 0.2% 5.16 [-3.52, 13.84]
Subtotal (95% CI) 11 10 0.2% 5.16 [-3.52, 13.84]
Heterogeneity: Not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2.2.3 individual_CES-D
Burgio 2003 -2.64 13.6817 61 0 13.6817 57 0.6% -2.64 [-7.58, 2.30]
Losada 2004 2.8 10.9971 15 4.8 7.8367 4 0.2% -2.00 [-11.48, 7.48]
Subtotal (95% CI) 76 61 0.8% -2.50 [-6.88, 1.88]
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.91); I² = 0%
Test for overall effect: Z = 1.12 (P = 0.26)
2.2.4 individual-BSI
Quayhagen 2000 0.03 0.7361 29 -0.03 0.5056 15 49.7% 0.06 [-0.31, 0.43]
Subtotal (95% CI) 29 15 49.7% 0.06 [-0.31, 0.43]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
2.2.5 tech-based_score
Chang 1999 -0.08 0.71 34 0 0.9 31 46.6% -0.08 [-0.48, 0.32]
Subtotal (95% CI) 34 31 46.6% -0.08 [-0.48, 0.32]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 271 213 100.0% -0.08 [-0.46, 0.31]
Heterogeneity: Tau² = 0.04; Chi² = 8.16, df = 7 (P = 0.32); I² = 14%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi² = 6.36, df = 4 (P = 0.17), I² = 37.1%
-20
-10
0
10
20
Favours [experimental]
Favours [control]

PSYCHOEDUCATIONAL INTERVENTIONS AND SKILL TRAINING

Caregiver burden



Depression


Experimental
Control
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
3.3.1 group_MADRS
De Rotrou 2011 -0.17 10.6814 72 1.24 13.5705 69 3.2% -1.41 [-5.45, 2.63]
Subtotal (95% CI) 72 69 3.2% -1.41 [-5.45, 2.63]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
3.3.2 group_CES-D
Losada 2011 -4.62 15.6578 68 -0.64 16.9953 50 1.5% -3.98 [-9.98, 2.02]
Ostwald 1999 -0.54 11.0932 51 1.51 11.4621 30 2.1% -2.05 [-7.16, 3.06]
Subtotal (95% CI) 119 80 3.6% -2.86 [-6.75, 1.03]
Heterogeneity: Tau² = 0.00; Chi² = 0.23, df = 1 (P = 0.63); I² = 0%
Test for overall effect: Z = 1.44 (P = 0.15)
3.3.3 individual_CES-D
Bourgeois 2002 4.1 13.2261 20 3.2 9.8343 19 1.1% 0.90 [-6.39, 8.19]
Burns 2003 0.1 13.2647 38 1.4 16.2559 37 1.2% -1.30 [-8.02, 5.42]
Joling 2012 1.51 10.6604 96 2.91 9.4759 96 6.0% -1.40 [-4.25, 1.45]
Subtotal (95% CI) 154 152 8.3% -1.12 [-3.59, 1.35]
Heterogeneity: Tau² = 0.00; Chi² = 0.33, df = 2 (P = 0.85); I² = 0%
Test for overall effect: Z = 0.89 (P = 0.37)
3.3.4 individual_CES-D short
Judge 2012 -0.72 4.6431 59 0.06 4.7199 59 13.2% -0.78 [-2.47, 0.91]
Subtotal (95% CI) 59 59 13.2% -0.78 [-2.47, 0.91]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
3.3.5 individual_HADS
Livingstone 2013 -0.2 5.5145 172 0.6 5.6304 87 16.0% -0.80 [-2.24, 0.64]
Subtotal (95% CI) 172 87 16.0% -0.80 [-2.24, 0.64]
Heterogeneity: Not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
3.3.6 tech-based_CES-D
Beauchamp 2005 -1.4 14.7514 150 1 15.5043 149 4.4% -2.40 [-5.83, 1.03]
Blom 2015 -2.35 8.21 149 0.34 7.51 96 10.5% -2.69 [-4.69, -0.69]
Gallagher-Thompson 2010 -2.25 14.0387 36 -0.8 15.6198 34 1.2% -1.45 [-8.42, 5.52]
Kajiyama 2013 -2.52 10.7421 46 -0.77 11.9094 57 2.8% -1.75 [-6.13, 2.63]
Subtotal (95% CI) 381 336 18.8% -2.45 [-4.01, -0.88]
Heterogeneity: Tau² = 0.00; Chi² = 0.23, df = 3 (P = 0.97); I² = 0%
Test for overall effect: Z = 3.06 (P = 0.002)
3.3.7 tech-based_BDI
Cristancho-Lacroix 2015 1.2 14.6083 25 -0.2 9.7806 24 1.2% 1.40 [-5.54, 8.34]
Subtotal (95% CI) 25 24 1.2% 1.40 [-5.54, 8.34]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
3.3.8 telephone_CES-D
Au 2019 -4.67 11.2023 56 1.63 14.2044 55 2.4% -6.30 [-11.06, -1.54]
Tremont 2015 -2.89 14.1672 133 0.43 14.09 117 4.2% -3.32 [-6.83, 0.19]
Subtotal (95% CI) 189 172 6.6% -4.37 [-7.19, -1.54]
Heterogeneity: Tau² = 0.00; Chi² = 0.97, df = 1 (P = 0.32); I² = 0%
Test for overall effect: Z = 3.03 (P = 0.002)
3.3.9 telephone_GDS
Tremont 2008 -0.56 7.0938 16 1.88 8.9857 17 1.8% -2.44 [-7.95, 3.07]
Subtotal (95% CI) 16 17 1.8% -2.44 [-7.95, 3.07]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
3.3.10 group_MAACL
Coon 2003 -1.4 1.7742 41 1.9 1.7762 44 27.4% -3.30 [-4.06, -2.54]
Subtotal (95% CI) 41 44 27.4% -3.30 [-4.06, -2.54]
Heterogeneity: Not applicable
Test for overall effect: Z = 8.56 (P < 0.00001)
Total (95% CI) 1228 1040 100.0% -2.14 [-2.90, -1.38]
Heterogeneity: Tau² = 0.40; Chi² = 19.78, df = 16 (P = 0.23); I² = 19%
Test for overall effect: Z = 5.52 (P < 0.00001)
Test for subgroup differences: Chi² = 18.01, df = 9 (P = 0.04), I² = 50.0%
-10 -5 0 5 10
Favours [experimental] Favours [control]

Anxiety



Caregiver stress – group interventions



Caregiver stress – interventions on technological support



Quality of life - Interventi individuali



Self-efficacy



SUPPORTIVE INTERVENTIONS

Caregiver burden



Depression



COGNITIVE BEHAVIORAL INTERVENTIONS

Caregiver burden



Depression



Anxiety



MULTICOMPONENT INTERVENTIONS

Caregiver burden



Depression


Experimental
Control
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
7.2.1 carer only_CES-D
Boots 2018 -2.37 11.5955 41 0.17 12.4759 40 3.7% -2.54 [-7.79, 2.71]
Davis 2011 -3.21 17.8799 24 -3.5 11.2546 22 2.1% 0.29 [-8.27, 8.85]
Finkel 2007 0 0 0 0 0 0 Not estimable
Gaugler 2015 -3.74 13.6341 17 1.26 15.0835 19 1.8% -5.00 [-14.38, 4.38]
Martindale-Adams 2013 -1.4 8.283 77 -1 9.3404 77 5.5% -0.40 [-3.19, 2.39]
Mohide 1990 -0.05 16.3969 22 2.8 12.756 20 2.0% -2.85 [-11.69, 5.99]
Subtotal (95% CI) 181 178 15.1% -1.15 [-3.37, 1.07]
Heterogeneity: Tau² = 0.00; Chi² = 1.45, df = 4 (P = 0.84); I² = 0%
Test for overall effect: Z = 1.01 (P = 0.31)
7.2.2 carer only_GDS
Mittelman 2004 -1.1 5 203 0.3 6 203 6.7% -1.40 [-2.47, -0.33]
Newcomer 1999 -0.04 4.8053 988 0.28 4.951 922 6.9% -0.32 [-0.76, 0.12]
Yoo 2018 -2.2 3.8 19 1.3 4.4 19 5.7% -3.50 [-6.11, -0.89]
Subtotal (95% CI) 1210 1144 19.2% -1.26 [-2.59, 0.08]
Heterogeneity: Tau² = 0.95; Chi² = 8.35, df = 2 (P = 0.02); I² = 76%
Test for overall effect: Z = 1.85 (P = 0.06)
7.2.3 carer only_BSI-d
Hebert 1994 -0.23 5.55 23 -1.09 5.6708 18 5.0% 0.86 [-2.61, 4.33]
Subtotal (95% CI) 23 18 5.0% 0.86 [-2.61, 4.33]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
7.2.4 carer only_PHQ4-d
Berwig 2017 -0.32 1.44 41 0.08 1.4 40 6.8% -0.40 [-1.02, 0.22]
Subtotal (95% CI) 41 40 6.8% -0.40 [-1.02, 0.22]
Heterogeneity: Not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
7.2.5 carer only_HAMD-d
Shata 2017 -9.87 4.05 55 0.33 0.51 59 6.7% -10.20 [-11.28, -9.12]
Subtotal (95% CI) 55 59 6.7% -10.20 [-11.28, -9.12]
Heterogeneity: Not applicable
Test for overall effect: Z = 18.54 (P < 0.00001)
7.2.6 dyadic_CES-D
Gaugler 2019 5.89 20.83 73 3.44 17.2331 79 3.2% 2.45 [-3.66, 8.56]
Gitlin 2003 -0.73 6.6853 700 -0.14 6.6853 387 6.8% -0.59 [-1.42, 0.24]
Gitlin 2008 -1.5 13.8023 27 1.1 13.4077 29 2.6% -2.60 [-9.74, 4.54]
Graff 2006 -6.3 9.2542 68 1.7 11.3972 67 5.0% -8.00 [-11.51, -4.49]
Prick 2015 2.78 9.7235 57 0.36 11.8338 54 4.5% 2.42 [-1.62, 6.46]
Subtotal (95% CI) 925 616 22.1% -1.41 [-5.03, 2.21]
Heterogeneity: Tau² = 12.09; Chi² = 20.22, df = 4 (P = 0.0005); I² = 80%
Test for overall effect: Z = 0.76 (P = 0.45)
7.2.7 dyadic_GDS
Bruvik 2013 0 9.311 115 0 8.0659 115 5.9% 0.00 [-2.25, 2.25]
Martin-Cook 2005 -0.18 2.9138 23 -0.32 3.126 24 6.3% 0.14 [-1.59, 1.87]
Waldorff 2012 0.96 5.8834 163 0.26 5.0399 167 6.6% 0.70 [-0.48, 1.88]
Subtotal (95% CI) 301 306 18.9% 0.44 [-0.46, 1.33]
Heterogeneity: Tau² = 0.00; Chi² = 0.45, df = 2 (P = 0.80); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.34)
7.2.8 dyadic_MADRS
Bottino 2005 -3.83 5.8794 6 -2.29 6.1632 7 2.9% -1.54 [-8.10, 5.02]
Subtotal (95% CI) 6 7 2.9% -1.54 [-8.10, 5.02]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
7.2.9 dyadi_BDI
Uyar 2019 -1.94 11.3817 30 5.41 11.314 31 3.4% -7.35 [-13.05, -1.65]
Subtotal (95% CI) 30 31 3.4% -7.35 [-13.05, -1.65]
Heterogeneity: Not applicable
Test for overall effect: Z = 2.53 (P = 0.01)
Total (95% CI) 2772 2399 100.0% -1.79 [-3.27, -0.32]
Heterogeneity: Tau² = 8.21; Chi² = 334.08, df = 20 (P < 0.00001); I² = 94%
Test for overall effect: Z = 2.38 (P = 0.02)
Test for subgroup differences: Chi² = 283.72, df = 8 (P < 0.00001), I² = 97.2%
-20 -10 0 10 20
Favours [experimental] Favours [control]

Quality of life



MEDITATION/MINDFULNESS

Caregiver burden



Caregiver stress



Depression



Anxiety



REVIEW QUESTION 15a. What is the safety and efficacy of acetylcholinesterase inhibitors and memantine for the treatment of cognitive symptoms in people with Alzheimer's dementia and how should they be monitored?

Acetylcholinesterase inhibitors vs placebo – MMSE (AD not stratified for severity)



Acetylcholinesterase inhibitors vs placebo – ADAS-Cog (AD not stratified for severity)



Acetylcholinesterase inhibitors vs placebo – ADCS-ADL (AD not stratified for severity)



Acetylcholinesterase inhibitors vs placebo – NPI (AD not stratified for severity)



Acetylcholinesterase inhibitors vs placebo – CIBIC+ (AD not stratified for severity)



Acetylcholinesterase inhibitors vs placebo – adverse events (AD not stratified for severity)



Acetylcholinesterase inhibitors vs placebo – MMSE (AD mild-moderate)



Acetylcholinesterase inhibitors vs placebo – ADAS-Cog (AD mild-moderate)



Acetylcholinesterase inhibitors vs placebo – ADCS-ADL (AD mild-moderate)



Acetylcholinesterase inhibitors vs placebo – NPI (AD mild-moderate)



Acetylcholinesterase inhibitors vs placebo – CIBIC+ (AD mild-moderate)



Acetylcholinesterase inhibitors vs placebo – Discontinuation due to adverse events (AD mild-moderate)



Acetylcholinesterase inhibitors vs placebo – MMSE (AD moderate-severe)



Acetylcholinesterase inhibitors vs placebo – ADCS-ADL (AD moderate-severe)



Acetylcholinesterase inhibitors vs placebo – NPI (AD moderate-severe)



Acetylcholinesterase inhibitors vs placebo – CIBIC+ (AD moderate-severe)



Acetylcholinesterase inhibitors vs placebo – Discontinuation due to adverse events (AD moderate-severe)



REVIEW QUESTION 15b. What is the safety and efficacy of acetylcholinesterase inhibitors and memantine for the treatment of cognitive symptoms in people with Mild cognitive impairment (MCI) and how should they be monitored?

Donepezil for Mild cognitive impairment – MMSE



Acetylcholinesterase inhibitors for Mild cognitive impairment – ADAS-Cog



Acetylcholinesterase inhibitors for Mild cognitive impairment – ADCS-ADL-MCI



Donepezil for Mild cognitive impairment – CDR-SB



Acetylcholinesterase inhibitors for Mild cognitive impairment – adverse events



Acetylcholinesterase inhibitors for Mild cognitive impairment – serious adverse events



Acetylcholinesterase inhibitors for Mild cognitive impairment – mortality



Acetylcholinesterase inhibitors for Mild cognitive impairment – withdrawal due to adverse events



REVIEW QUESTION 15c. What is the safety and efficacy of biological drugs (active and passive immunotherapy) for the treatment of cognitive symptoms in people with Alzheimer's dementia or Mild cognitive impairment (MCI) and how should they be monitored?

Active immunotherapies against Aβ – adverse events



Active immunotherapies against Aβ – serious adverse events



Passive immunotherapies against Aβ – adverse events



Passive immunotherapies against Aβ – serious adverse events



Passive immunotherapies against Aβ – ARIA-E



Passive immunotherapies against Aβ – ARIA-E in subjects homozygous for *ApoE ε4* genotype



Passive immunotherapies against Aβ – ARIA-E in subjects heterozygotes for ApoE ε4 genotype



Passive immunotherapies against Aβ – ARIA-E in subjects not carrying the ApoE ε4 genotype



Passive immunotherapies against Aβ – ARIA-H



Passive immunotherapies against Aβ – ARIA-H in subjects not carrying the ApoE ε4 genotype



Passive immunotherapies against Aβ – ARIA-H in subjects homozygous for *ApoE ε4* genotype



Passive immunotherapies against Aβ – ARIA-H subjects heterozygotes for ApoE ε4 genotype



Passive immunotherapies against Tau protein – adverse events

Study or Subgroup	Intervention Events	Intervention Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
1.2.1 Semorinemab						
Monteiro 2023	112	135	107	132	20.6%	1.02 [0.91, 1.15]
Teng 2022	286	311	121	130	79.4%	0.99 [0.93, 1.05]
Subtotal (95% CI)		**446**		**262**	**100.0%**	**1.00 [0.95, 1.05]**
Total events	398		228			
Heterogeneity: Tau² = 0.00; Chi² = 0.36, df = 1 (P = 0.55); I² = 0%						
Test for overall effect: Z = 0.18 (P = 0.85)						
1.2.2 Tilavonemab						
Florian 2023	306	337	108	116	100.0%	0.98 [0.92, 1.04]
Subtotal (95% CI)		**337**		**116**	**100.0%**	**0.98 [0.92, 1.04]**
Total events	306		108			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.82 (P = 0.41)						
1.2.3 Gosuranemab						
Shulman 2023	381	436	181	214	100.0%	1.03 [0.97, 1.11]
Subtotal (95% CI)		**436**		**214**	**100.0%**	**1.03 [0.97, 1.11]**
Total events	381		181			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.95 (P = 0.34)						

Test for subgroup differences: Chi² = 1.59, df = 2 (P = 0.45), I² = 0%



Passive immunotherapies against Tau protein – serious adverse events

Study or Subgroup	Intervention Events	Intervention Total	Placebo Events	Placebo Total	Weight	Risk Ratio M-H, Random, 95% CI
1.5.1 Semorinemab						
Monteiro 2023	23	135	23	132	53.1%	0.98 [0.58, 1.65]
Teng 2022	48	311	14	130	46.9%	1.43 [0.82, 2.51]
Subtotal (95% CI)		**446**		**262**	**100.0%**	**1.17 [0.80, 1.72]**
Total events	71		37			
Heterogeneity: Tau² = 0.00; Chi² = 0.96, df = 1 (P = 0.33); I² = 0%						
Test for overall effect: Z = 0.80 (P = 0.42)						
1.5.2 Tilavonemab						
Florian 2023	58	337	26	116	100.0%	0.77 [0.51, 1.16]
Subtotal (95% CI)		**337**		**116**	**100.0%**	**0.77 [0.51, 1.16]**
Total events	58		26			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.26 (P = 0.21)						
1.5.3 Gosuranemab						
Shulman 2023	50	436	26	214	100.0%	0.94 [0.61, 1.47]
Subtotal (95% CI)		**436**		**214**	**100.0%**	**0.94 [0.61, 1.47]**
Total events	50		26			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.25 (P = 0.80)						

Test for subgroup differences: Chi² = 2.16, df = 2 (P = 0.34), I² = 7.4%



Passive immunotherapies against Aβ – CDR-SB



Donanemab – iADRS

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Mintun 2021	-6.86	12.9907	131	-10.06	12.8077	126	18.5%	3.20 [0.05, 6.35]
Sims 2023	-10.19	13.2772	583	-13.22	11.2576	444	81.5%	3.03 [1.53, 4.53]
Total (95% CI)			**714**			**570**	**100.0%**	**3.06 [1.70, 4.42]**

Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.92); I² = 0%
Test for overall effect: Z = 4.42 (P < 0.00001)



Donanemab – MMSE

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
2.4.2 Donanemab								
Mintun 2021	-2.35	4.418	131	-2.98	4.3777	126	13.0%	0.63 [-0.45, 1.71]
Sims 2023	-2.75	3.7417	600	-3.22	3.8487	679	87.0%	0.47 [0.05, 0.89]
Subtotal (95% CI)			**731**			**805**	**100.0%**	**0.49 [0.10, 0.88]**

Heterogeneity: Tau² = 0.00; Chi² = 0.07, df = 1 (P = 0.79); I² = 0%
Test for overall effect: Z = 2.48 (P = 0.01)



Donanemab – ADCS-ADL

Study or Subgroup	Experimental Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
2.6.1 Donanemab								
Mintun 2021	-3.98	8.4468	131	-5.2	8.3402	126	17.1%	1.22 [-0.83, 3.27]
Sims 2023	-4.57	8.2933	591	-6.32	8.5108	661	82.9%	1.75 [0.82, 2.68]
Subtotal (95% CI)			**722**			**787**	**100.0%**	**1.66 [0.81, 2.51]**

Heterogeneity: Tau² = 0.00; Chi² = 0.21, df = 1 (P = 0.64); I² = 0%
Test for overall effect: Z = 3.83 (P = 0.0001)



Passive immunotherapies against Aβ – amyloid PET



REVIEW QUESTION 16a. What effect does modifying risk factors (repositioning drugs acting on possible etiological causes of dementia) have on slowing the progression of dementia?

Antidiabetic drugs – ADAS-Cog



Antidiabetic drugs – adverse events



Non steroidal anti-inflammatory drugs – ADAS-Cog



Non steroidal anti-inflammatory drugs – MMSE



Non steroidal anti-inflammatory drugs – ADCS-ADL



Non steroidal anti-inflammatory drugs – NPI



Non steroidal anti-inflammatory drugs – CIBIC+



Non steroidal anti-inflammatory drugs – adverse events



Non steroidal anti-inflammatory drugs – serious adverse events

Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Risk Ratio M-H, Random, 95% CI
Aisen 2003	51	240	15	111	7.8%	1.57 [0.93, 2.67]
Bentham 2008	63	156	52	154	21.0%	1.20 [0.89, 1.60]
De Jong 2008	5	26	1	25	0.6%	4.81 [0.60, 38.32]
Green 2009	195	860	163	821	37.8%	1.14 [0.95, 1.37]
Reines 2004	61	346	54	346	17.1%	1.13 [0.81, 1.58]
Soininen 2007	73	285	32	105	15.9%	0.84 [0.59, 1.19]
Total (95% CI)		**1913**		**1562**	**100.0%**	**1.13 [0.97, 1.32]**
Total events	448		317			

Heterogeneity: Tau² = 0.01; Chi² = 6.30, df = 5 (P = 0.28); I² = 21%
Test for overall effect: Z = 1.57 (P = 0.12)



Statins – ADAS-Cog

Study or Subgroup	Statins Mean	Statins SD	Statins Total	PL Mean	PL SD	PL Total	Weight	Mean Difference IV, Random, 95% CI
3.1.1 Atorvastatin								
Feldman 2010	3.61	6.91	236	4.12	7	278	44.6%	-0.51 [-1.72, 0.70]
Sparks 2005	-2.2	7.5	21	1.8	5.9	25	8.8%	-4.00 [-7.95, -0.05]
Subtotal (95% CI)			**257**			**303**	**53.4%**	**-1.73 [-4.99, 1.53]**
Heterogeneity: Tau² = 3.87; Chi² = 2.74, df = 1 (P = 0.10); I² = 63%								
Test for overall effect: Z = 1.04 (P = 0.30)								
3.1.2 Simvastatin								
Sano 2011	5.79	7.76	204	5.36	6.95	202	38.1%	0.43 [-1.00, 1.86]
Simons 2002	3.4	7	20	4.1	6.5	24	8.5%	-0.70 [-4.72, 3.32]
Subtotal (95% CI)			**224**			**226**	**46.6%**	**0.30 [-1.05, 1.65]**
Heterogeneity: Tau² = 0.00; Chi² = 0.27, df = 1 (P = 0.60); I² = 0%								
Test for overall effect: Z = 0.44 (P = 0.66)								
Total (95% CI)			**481**			**529**	**100.0%**	**-0.47 [-1.72, 0.77]**
Heterogeneity: Tau² = 0.52; Chi² = 4.51, df = 3 (P = 0.21); I² = 33%								
Test for overall effect: Z = 0.75 (P = 0.45)								
Test for subgroup differences: Chi² = 1.27, df = 1 (P = 0.26), I² = 21.3%								



Statins – MMSE

Study or Subgroup	Statins Mean	Statins SD	Statins Total	PL Mean	PL SD	PL Total	Weight	Mean Difference IV, Random, 95% CI
3.2.1 Atorvastatin								
Feldman 2010	-0.96	3.38	236	-1.35	3.5	278	35.9%	0.39 [-0.21, 0.99]
Sparks 2005	-0.77	2.7	32	-2.42	3.2	31	18.8%	1.65 [0.19, 3.11]
Subtotal (95% CI)			**268**			**309**	**54.7%**	**0.84 [-0.35, 2.02]**
Heterogeneity: Tau² = 0.47; Chi² = 2.44, df = 1 (P = 0.12); I² = 59%								
Test for overall effect: Z = 1.39 (P = 0.17)								
3.2.2 Simvastatin								
Sano 2011	-2.47	3.8	204	-2.28	4.08	202	32.1%	-0.19 [-0.96, 0.58]
Simons 2002	-0.6	3.1	24	-2.7	3.39	20	13.2%	2.10 [0.16, 4.04]
Subtotal (95% CI)			**228**			**222**	**45.3%**	**0.78 [-1.44, 2.99]**
Heterogeneity: Tau² = 2.06; Chi² = 4.65, df = 1 (P = 0.03); I² = 78%								
Test for overall effect: Z = 0.69 (P = 0.49)								
Total (95% CI)			**496**			**531**	**100.0%**	**0.67 [-0.17, 1.51]**
Heterogeneity: Tau² = 0.42; Chi² = 8.04, df = 3 (P = 0.05); I² = 63%								
Test for overall effect: Z = 1.55 (P = 0.12)								
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.96), I² = 0%								



Statins – NPI



Statins – adverse events



Antihypertensive drugs – ADAS-Cog



Antihypertensive drugs – MMSE



Antihypertensive drugs – adverse events



REVIEW QUESTION 17a. How effective is the co-prescription of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease?

AChEI + memantine vs AChEI + placebo – MMSE



AChEI + memantine vs AChEI + placebo – ADAS-Cog



AChEI + memantine vs AChEI + placebo – ADL



AChEI + memantine vs AChEI + placebo – CIBIC+



AChEI + memantine vs AChEI + placebo – NPI



AChEI + memantine vs AChEI + placebo – adverse events



AChEI + memantine vs AChEI + placebo – withdrawal due to adverse events



AChEI + memantine vs AChEI as monotherapy – MMSE



AChEI + memantine vs memantina + placebo – MMSE



AChEI + memantine vs memantine + placebo – ADCS-ADL



AChEI + memantine vs memantine + placebo – adverse events



REVIEW QUESTION 17b. When should treatment with donepezil, galantamine, rivastigmine, memantine be withdrawn for people with Alzheimer's disease?

AChEI withdrawal vs continuation – MMSE



REVIEW QUESTION 18a. What is the comparative effectiveness of donepezil, galantamine, memantine and rivastigmine for cognitive enhancement in dementia associated with Parkinson's disease?

Acetylcholinesterase inhibitors and memantine for the treatment of PDD – MMSE



Acetylcholinesterase inhibitors and memantine for the treatment of PDD – ADAS-Cog



Acetylcholinesterase inhibitors and memantine for the treatment of PDD – CIBIC+



Acetylcholinesterase inhibitors and memantine for the treatment of PDD – ADL



Acetylcholinesterase inhibitors and memantine for the treatment of PDD – NPI-10 items



Acetylcholinesterase inhibitors and memantine for the treatment of PDD – UPDRS-III



Acetylcholinesterase inhibitors and memantine for the treatment of PDD – adverse events



Acetylcholinesterase inhibitors and memantine for the treatment of PDD – withdrawal due to adverse events



REVIEW QUESTION 18b. What is the comparative effectiveness of donepezil, galantamine, memantine and rivastigmine for cognitive enhancement in dementia with Lewy bodies?

Acetylcholinesterase inhibitors and memantine for the treatment of DLB – MMSE



Acetylcholinesterase inhibitors and memantine for the treatment of DLB – NPI-10 items



Acetylcholinesterase inhibitors and memantine for the treatment of DLB – UPDRS-III



Acetylcholinesterase inhibitors and memantine for the treatment of DLB – adverse events



Acetylcholinesterase inhibitors and memantine for the treatment of DLB – withdrawal due to adverse events



REVIEW QUESTION 20a. What are the most effective non-pharmacological interventions for supporting cognitive functioning in people living with dementia?

REVIEW QUESTION 20b. What are the most effective non-pharmacological interventions for supporting functional ability in people living with dementia?

REVIEW QUESTION 20c. What are the most effective non-pharmacological interventions to support wellbeing in people living with dementia?

REVIEW QUESTION 20d. What are the most effective methods of supporting people living with dementia to reduce harm and stay independent?

ACUPUNCTURE

MMSE



PHYSICAL EXERCISE

Dance

MMSE



Aerobic exercise

MMSE



MMSE



Functional activities



Non-aerobic exercise

MMSE



Functional activities



Aerobic/non-aerobic combined exercise

MMSE



Functional activities



Quality of life



Light therapy

MMSE



NUTRITIONAL INTERVENTIONS

MMSE



ADAS-Cog



Study or Subgroup	Supplement Mean	SD	Total	PL Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
1.2.3 Sodium oligomannate								
Wang 2020-600mg	-1.4	6.5	76	-1.5	7	41	23.8%	0.10 [-2.49, 2.69]
Wang 2020-900mg	-2.6	5.7	83	-1.5	7	42	24.1%	-1.10 [-3.55, 1.35]
Xiao 2021	-1.89	9.1449	408	0.26	8.6524	410	25.8%	-2.15 [-3.37, -0.93]
Zhang 2022	0	1.41	36	7.5	0.5	12	26.3%	-7.50 [-8.04, -6.96]
Subtotal (95% CI)			**603**			**505**	**100.0%**	**-2.77 [-6.80, 1.26]**

Heterogeneity: Tau² = 16.01; Chi² = 103.90, df = 3 (P < 0.00001); I² = 97%
Test for overall effect: Z = 1.35 (P = 0.18)

Mean Difference IV, Random, 95% CI
-20 -10 0 10 20
Favours [experimental] Favours [control]

Functional abilities



Study or Subgroup	Supplement Mean	SD	Total	PL Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI
1.4.1 Folic acid								
Chen 2016	0.06	10.88	61	0.13	13.42	60	57.7%	-0.01 [-0.36, 0.35]
Connelly 2008	0.61	3.6	23	-2.06	4.17	18	42.3%	0.68 [0.04, 1.31]
Subtotal (95% CI)			**84**			**78**	**100.0%**	**0.28 [-0.38, 0.95]**

Heterogeneity: Tau² = 0.16; Chi² = 3.39, df = 1 (P = 0.07); I² = 70%
Test for overall effect: Z = 0.84 (P = 0.40)

1.4.2 Gingko biloba								
Herrschaft 2012	0.11	0.38	200	-0.04	0.32	202	17.4%	0.43 [0.23, 0.62]
Ihl 2012	0.15	0.29	202	-0.01	0.32	202	17.4%	0.52 [0.32, 0.72]
Kanowski 2003	0.8	2.1	106	0.4	2.03	99	16.2%	0.19 [-0.08, 0.47]
Napryenko 2007	1.86	2.7	198	-0.9	2.44	197	17.2%	1.07 [0.86, 1.28]
Nikolova 2013	0.07	2.15	196	-0.26	2.22	201	17.4%	0.15 [-0.05, 0.35]
van Dongen 2000	-1.4	4.8	79	-1.4	5.5	40	14.4%	0.00 [-0.38, 0.38]
Subtotal (95% CI)			**981**			**941**	**100.0%**	**0.41 [0.11, 0.71]**

Heterogeneity: Tau² = 0.12; Chi² = 51.36, df = 5 (P < 0.00001); I² = 90%
Test for overall effect: Z = 2.66 (P = 0.008)

1.4.3 Huperzine A								
Dong 2012	-34.9	11.06	10	-45.45	19.25	11	8.3%	0.64 [-0.25, 1.52]
Liu 1995	3.6	14.84	14	-2.6	15.77	14	10.2%	0.39 [-0.36, 1.14]
Rafii 2011	-1.015	8.47	140	-2.64	8.66	70	20.9%	0.19 [-0.10, 0.48]
Xu 1997	3.58	13.41	50	-1.25	9.36	53	18.2%	0.42 [0.03, 0.81]
Yang 2003	6.6	10.19	35	0	8.56	30	15.3%	0.69 [0.19, 1.19]
Zhang 2002	2.39	4.88	98	0.48	5.01	99	21.1%	0.38 [0.10, 0.67]
Zhou 2004	5.9	3.35	12	-2.25	2.98	12	6.0%	2.48 [1.37, 3.59]
Subtotal (95% CI)			**359**			**289**	**100.0%**	**0.54 [0.23, 0.85]**

Heterogeneity: Tau² = 0.10; Chi² = 17.13, df = 6 (P = 0.009); I² = 65%
Test for overall effect: Z = 3.44 (P = 0.0006)

1.4.5 Omega 3								
Quinn 2010	11.51	15.2565	240	10.43	12.9373	160	77.0%	0.07 [-0.13, 0.28]
Shinto 2014	2.5	1	13	2.9	0.7	13	23.0%	-0.45 [-1.23, 0.33]
Subtotal (95% CI)			**253**			**173**	**100.0%**	**-0.05 [-0.48, 0.39]**

Heterogeneity: Tau² = 0.05; Chi² = 1.62, df = 1 (P = 0.20); I² = 38%
Test for overall effect: Z = 0.21 (P = 0.84)

1.4.6 Sodium oligomannate								
Wang 2020-600mg	-0.5	7.7	76	-1.1	7.8	41	15.4%	0.08 [-0.30, 0.46]
Wang 2020-900mg	-0.5	8.3	83	-1.1	7.8	42	15.9%	0.07 [-0.30, 0.44]
Xiao 2021	-1.15	8.2201	408	-1.41	7.9314	410	45.4%	0.03 [-0.10, 0.17]
Zhang 2022	2.39	4.88	98	0.48	5.01	99	23.3%	0.38 [0.10, 0.67]
Subtotal (95% CI)			**665**			**592**	**100.0%**	**0.13 [-0.04, 0.30]**

Heterogeneity: Tau² = 0.01; Chi² = 4.89, df = 3 (P = 0.18); I² = 39%
Test for overall effect: Z = 1.47 (P = 0.14)

Std. Mean Difference IV, Random, 95% CI
-2 -1 0 1 2
Favours [control] Favours [experimental]

ADCS-ADL – other supplements



Quality of life - Ginkgo biloba



Quality of life – Ketogenic diet



COGNITIVE INTERVENTIONS

Cognitive rehabilitation (individual)

ADL



Functional activities



Quality of life



Cognitive stimulation (group)

ADAS-Cog



MMSE



Functional abilities



Quality of life



Quality of life



Cognitive stimulation (individual)

MMSE



ADL



Cognitive training (group)

MMSE



ADL



Cognitive training (individual)

MMSE



ADL



MUSIC THERAPY

MMSE - receptive music therapy



MMSE - active music therapy



PSYCHOTHERAPY

MMSE



TRANSCRANICAL STIMULATION

Repetitive Transcranial Magnetic Stimulation

MMSE

Study or Subgroup	rTMS Mean	rTMS SD	rTMS Total	sham Mean	sham SD	sham Total	Weight	Mean Difference IV, Random, 95% CI
2.5.1 mild to moderate dementia								
Ahmed 2012	4.2	1.5	10	-1	3.2	11	15.6%	5.20 [3.09, 7.31]
Cotelli 2011	-0.5	3.5	12	0.2	2.5	12	14.4%	-0.70 [-3.13, 1.73]
Jia 2021	1.46	7.95	35	0.56	9.17	34	9.5%	0.90 [-3.15, 4.95]
Khedr 2020	0.91	3.88	18	1	3.34	15	14.3%	-0.09 [-2.55, 2.37]
Koch 2022	-0.3	13.32	25	-1.75	13.45	25	4.2%	1.45 [-5.97, 8.87]
Lee 2016	2	4.57	18	3	4.56	8	10.2%	-1.00 [-4.80, 2.80]
Rabey 2013	3.76	3.5	7	0.47	3.3	8	11.2%	3.29 [-0.17, 6.75]
Yao 2022	2.93	5.39	15	0.2	5.92	12	8.9%	2.73 [-1.59, 7.05]
Zhao 2017	3.3	4.98	17	1.4	4.22	13	11.6%	1.90 [-1.40, 5.20]
Subtotal (95% CI)			**157**			**138**	**100.0%**	**1.57 [-0.14, 3.29]**

Heterogeneity: Tau² = 3.77; Chi² = 19.49, df = 8 (P = 0.01); I² = 59%
Test for overall effect: Z = 1.79 (P = 0.07)



ADAS-Cog

Study or Subgroup	rTMS Mean	rTMS SD	rTMS Total	sham Mean	sham SD	sham Total	Weight	Mean Difference IV, Random, 95% CI
2.2.1 mild to moderate dementia								
Koch 2022	0.67	50.56	25	4.19	50.37	25	1.4%	-3.52 [-31.50, 24.46]
Yao 2022	-2.95	5.7	15	-0.7	4.64	12	72.6%	-2.25 [-6.15, 1.65]
Zhao 2017	-5.8	8.38	17	-3	9.48	13	26.0%	-2.80 [-9.31, 3.71]
Subtotal (95% CI)			**57**			**50**	**100.0%**	**-2.41 [-5.73, 0.91]**

Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 2 (P = 0.99); I² = 0%
Test for overall effect: Z = 1.42 (P = 0.15)



MoCA

Study or Subgroup	rTMS Mean	rTMS SD	rTMS Total	sham Mean	sham SD	sham Total	Weight	Mean Difference IV, Random, 95% CI
2.3.1 mild to moderate dementia								
Khedr 2020	1.17	5.37	18	0.8	6.75	15	38.9%	0.37 [-3.85, 4.59]
Yao 2022	2.93	6.28	15	0.4	4.42	12	42.4%	2.53 [-1.51, 6.57]
Zhao 2017	4	7.91	17	2	8.85	13	18.6%	2.00 [-4.11, 8.11]
Subtotal (95% CI)			**50**			**40**	**100.0%**	**1.59 [-1.04, 4.22]**

Heterogeneity: Tau² = 0.00; Chi² = 0.55, df = 2 (P = 0.76); I² = 0%
Test for overall effect: Z = 1.18 (P = 0.24)



ADL

Study or Subgroup	rTMS Mean	rTMS SD	rTMS Total	sham Mean	sham SD	sham Total	Weight	Std. Mean Difference IV, Random, 95% CI
2.4.1 mild to moderate dementia								
Cotelli 2011	0	1.9	12	0	2.3	12	22.7%	0.00 [-0.80, 0.80]
Khedr 2020	3.35	5.45	18	0.53	7.39	15	30.2%	0.43 [-0.26, 1.12]
Koch 2022	0.7	64.2	25	-7.54	67.74	25	47.2%	0.12 [-0.43, 0.68]
Subtotal (95% CI)			**55**			**52**	**100.0%**	**0.19 [-0.19, 0.57]**

Heterogeneity: Tau² = 0.00; Chi² = 0.73, df = 2 (P = 0.69); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.33)



Transcranial Direct-Current Stimulation

MMSE



PET THERAPY

MMSE



REMINESCENCE THERAPY (group)

MMSE



Functional abilities



Quality of life



REMINESCENCE THERAPY (individual)

MMSE



OCCUPATIONAL THERAPY

MMSE



ADL



Quality of life



REVIEW QUESTION 20e. What are the most effective non-pharmacological interventions for supporting cognitive functioning, functional ability and wellbeing in people with Mild Cognitive Impairment?

ACUPUNCTURE

MoCA



MMSE



ADAS-Cog



ART THERAPY

GDS



Anxiety



PHYSICAL EXERCISE

Dance

MoCA



MMSE



WMS-R LM



TMT-A



TMT-B



GDS

Study or Subgroup	dance Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Chang 2021	-0.66	1.772	62	0.17	2.2819	47	42.8%	-0.83 [-1.62, -0.04]
Dominguez 2018	-0.4	2	90	0.5	2.6	81	54.1%	-0.90 [-1.60, -0.20]
Zhu 2018	-2.1	5.5208	29	-3.2	5.9978	31	3.1%	1.10 [-1.81, 4.01]
Total (95% CI)			**181**			**159**	**100.0%**	**-0.81 [-1.32, -0.29]**

Heterogeneity: Tau² = 0.00; Chi² = 1.72, df = 2 (P = 0.42); I² = 0%
Test for overall effect: Z = 3.07 (P = 0.002)



Aerobic exercise

MMSE

Study or Subgroup	AE Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Avenali 2021	-0.42	3.3587	15	-0.77	3.7138	19	28.1%	0.35 [-2.03, 2.73]
Bademli 2019	3.27	2.7316	30	-1.18	1.4997	30	36.5%	4.45 [3.33, 5.57]
Kohanpour 2017	1.7	1.8732	10	-0.1	0.98	10	35.4%	1.80 [0.49, 3.11]
Total (95% CI)			**55**			**59**	**100.0%**	**2.36 [0.03, 4.69]**

Heterogeneity: Tau² = 3.56; Chi² = 14.47, df = 2 (P = 0.0007); I² = 86%
Test for overall effect: Z = 1.98 (P = 0.05)



MoCA

Study or Subgroup	AE Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Avenali 2021	-0.53	3.6838	15	-1.69	2.9462	19	23.1%	1.16 [-1.13, 3.45]
Tao 2019	0.88	1.96	17	1.1	1.48	20	76.9%	-0.22 [-1.36, 0.92]
Total (95% CI)			**32**			**39**	**100.0%**	**0.10 [-1.04, 1.24]**

Heterogeneity: Tau² = 0.10; Chi² = 1.12, df = 1 (P = 0.29); I² = 11%
Test for overall effect: Z = 0.17 (P = 0.87)



Non-aerobic exercise

MoCA

Study or Subgroup	nAE Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Hong 2017	1	3.998	10	0.42	5.9965	12	7.3%	0.58 [-3.62, 4.78]
Tao 2019	2.1	2.25	20	1.1	1.48	20	92.7%	1.00 [-0.18, 2.18]
Total (95% CI)			**30**			**32**	**100.0%**	**0.97 [-0.17, 2.11]**

Heterogeneity: Tau² = 0.00; Chi² = 0.04, df = 1 (P = 0.85); I² = 0%
Test for overall effect: Z = 1.67 (P = 0.09)



Digit Span Forward

Study or Subgroup	nAE Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Hong 2017	0.1	1.1043	10	0.08	1.5424	12	28.7%	0.02 [-1.09, 1.13]
Lu 2016	0.14	1.2856	22	0.17	1.11	23	71.3%	-0.03 [-0.73, 0.67]
Total (95% CI)			**32**			**35**	**100.0%**	**-0.02 [-0.61, 0.58]**

Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.94); I² = 0%
Test for overall effect: Z = 0.05 (P = 0.96)



Digit Span Backward



Aerobic/non-aerobic combined exercise

MMSE



GAMES AND VIDEOGAMES

Games and board games

MoCA



Videogames

MoCA



TMT-A



TMT-B

Study or Subgroup	VG Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Park 2020	-7.9	11.0801	18	-1.7	14.451	17	98.8%	-6.20 [-14.77, 2.37]
Schwenk 2016	6.4	118.9028	11	0.9	49.6313	9	1.2%	5.50 [-71.89, 82.89]
Total (95% CI)			**29**			**26**	**100.0%**	**-6.06 [-14.57, 2.46]**

Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 1 (P = 0.77); I² = 0%
Test for overall effect: Z = 1.39 (P = 0.16)



MULTIMODAL INTERVENTIONS

MMSE

Study or Subgroup	ME Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Jeong 2021	-0.08	3.0818	13	-0.38	3.0384	13	12.1%	0.30 [-2.05, 2.65]
Li 2021a	1.29	1.7329	42	-1.2	2.6314	42	26.8%	2.49 [1.54, 3.44]
Park 2019a	0.2	4.2945	25	-0.2	4.0873	24	12.1%	0.40 [-1.95, 2.75]
Shimada 2017	0	2.5126	154	-0.8	2.5126	154	31.8%	0.80 [0.24, 1.36]
Suzuki 2012	-0.47	3.1009	25	-0.44	3.1494	25	17.3%	-0.03 [-1.76, 1.70]
Total (95% CI)			**259**			**258**	**100.0%**	**1.00 [-0.01, 2.01]**

Heterogeneity: Tau² = 0.75; Chi² = 11.69, df = 4 (P = 0.02); I² = 66%
Test for overall effect: Z = 1.95 (P = 0.05)



ADAS-Cog

Study or Subgroup	ME Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Jeong 2021	-1.85	10.414	13	0.46	0.0965	1	13.7%	-2.31 [-7.97, 3.35]
Park 2019a	-1.6	4.172	25	0.4	3.895	24	86.3%	-2.00 [-4.26, 0.26]
Total (95% CI)			**38**			**25**	**100.0%**	**-2.04 [-4.14, 0.06]**

Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.92); I² = 0%
Test for overall effect: Z = 1.91 (P = 0.06)



MoCA

Study or Subgroup	ME Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Li 2021a	3.67	2.3426	42	-1.69	2.7277	42	48.5%	5.36 [4.27, 6.45]
Yang 2022	0.96	1.4796	55	-1.68	1.6206	57	51.5%	2.64 [2.07, 3.21]
Total (95% CI)			**97**			**99**	**100.0%**	**3.96 [1.29, 6.62]**

Heterogeneity: Tau² = 3.50; Chi² = 18.79, df = 1 (P < 0.0001); I² = 95%
Test for overall effect: Z = 2.91 (P = 0.004)



WMS-R LM

Study or Subgroup	ME Mean	SD	Total	usual care Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Shimada 2017	1.2	3.1408	154	0.3	3.7689	154	80.7%	0.90 [0.13, 1.67]
Suzuki 2012	5.13	5.5962	25	6.2	5.6689	25	19.3%	-1.07 [-4.19, 2.05]
Total (95% CI)			**179**			**179**	**100.0%**	**0.52 [-1.00, 2.04]**

Heterogeneity: Tau² = 0.59; Chi² = 1.44, df = 1 (P = 0.23); I² = 31%
Test for overall effect: Z = 0.67 (P = 0.50)



GDS



COGNITIVE INTERVENTIONS

Multimodal cognitive intervention (group) in residential care setting

MMSE



BADL



GDS



Cognitive training

MMSE



MoCA



GDS



IADL



NUTRITIONAL INTERVENTIONS

Polyunsaturated fatty acids

Digit Span



WAIS



Depressive symptoms



Vitamin B

WAIS



Digit Span



TRANSCRANIAL DIRECT-CURRENT STIMULATION

MMSE



REVIEW QUESTION 21a. Quali sono gli interventi farmacologici più efficaci per gestire i sintomi non cognitivi della malattia, come disturbi dello spettro della schizofrenia e altri disturbi psicotici, disturbi depressivi, cambiamenti comportamentali in persone con demenza?

ANTIDEPRESSANTS

CSDD



CSDD - stratified by drug



GDS


antidepressant
PL
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
1.2.1 escitalopram
An 2017 -3.75 4.4238 27 -2.85 4.9636 33 2.9% -0.90 [-3.28, 1.48]
Subtotal (95% CI) 27 33 2.9% -0.90 [-3.28, 1.48]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
1.2.2 vortioxetine
Jeong 2022* -0.59 1.0498 49 0 1.0498 51 97.1% -0.59 [-1.00, -0.18]
Subtotal (95% CI) 49 51 97.1% -0.59 [-1.00, -0.18]
Heterogeneity: Not applicable
Test for overall effect: Z = 2.81 (P = 0.005)
Total (95% CI) 76 84 100.0% -0.60 [-1.00, -0.19]
Heterogeneity: Tau² = 0.00; Chi² = 0.06, df = 1 (P = 0.80); I² = 0%
Test for overall effect: Z = 2.89 (P = 0.004)
Test for subgroup differences: Chi² = 0.06, df = 1 (P = 0.80), I² = 0%
-4
-2
0
2
4
Favours [experimental]
Favours [control]

NPI


antidepressant
PL
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
1.4.1 sertraline
Banerjee 2011* 2.02 15.4294 68 0 15.4294 41 12.6% 2.02 [-3.96, 8.00]
Finkel 2004 -4.7 17.6 121 -6.5 11.9996 119 18.3% 1.80 [-2.01, 5.61]
Lyketsos 2003 -8.9 24.9371 24 -3.7 18.5251 20 4.3% -5.20 [-18.06, 7.66]
Subtotal (95% CI) 213 180 35.2% 1.45 [-1.67, 4.56]
Heterogeneity: Tau² = 0.00; Chi² = 1.09, df = 2 (P = 0.58); I² = 0%
Test for overall effect: Z = 0.91 (P = 0.36)
1.4.2 mirtazapine
Banerjee 2011* -1.51 15.1885 76 0 15.1885 41 13.0% -1.51 [-7.28, 4.26]
Banerjee 2021 -8.8 23.9917 75 -9.2 26.3578 84 9.1% 0.40 [-7.43, 8.23]
Subtotal (95% CI) 151 125 22.2% -0.84 [-5.48, 3.81]
Heterogeneity: Tau² = 0.00; Chi² = 0.15, df = 1 (P = 0.70); I² = 0%
Test for overall effect: Z = 0.35 (P = 0.72)
1.4.3 citalopram
Porsteinsson 2014 -16.1 23.5329 94 -10.07 23.7573 92 10.9% -6.03 [-12.83, 0.77]
Zhou 2019 -6.92 13.9436 39 -3.15 10.8588 39 13.6% -3.77 [-9.32, 1.78]
Subtotal (95% CI) 133 131 24.4% -4.67 [-8.97, -0.38]
Heterogeneity: Tau² = 0.00; Chi² = 0.25, df = 1 (P = 0.61); I² = 0%
Test for overall effect: Z = 2.13 (P = 0.03)
1.4.4 bupropion
Maier 2020 -0.24 10.2584 54 -5.75 10.0019 54 18.2% 5.51 [1.69, 9.33]
Subtotal (95% CI) 54 54 18.2% 5.51 [1.69, 9.33]
Heterogeneity: Not applicable
Test for overall effect: Z = 2.83 (P = 0.005)
Total (95% CI) 551 490 100.0% 0.04 [-2.88, 2.96]
Heterogeneity: Tau² = 8.36; Chi² = 14.21, df = 7 (P = 0.05); I² = 51%
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Chi² = 12.71, df = 3 (P = 0.005), I² = 76.4%
-20
-10
0
10
20
Favours [antidepressant]
Favours [PL]

NPI - stratified by drug



ADL



ADL - stratified by drug



MMSE


antidepressant
PL
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
1.7.1 escitalopram
An 2017 1 5.8394 27 0.03 6.6839 33 2.0% 0.97 [-2.20, 4.14]
Subtotal (95% CI) 27 33 2.0% 0.97 [-2.20, 4.14]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
1.7.2 sertraline
Banerjee 2011* -0.55 4.1684 68 0 4.1684 41 6.5% -0.55 [-2.17, 1.07]
Finkel 2004 0 3.3 121 -0.6 3.2726 119 16.1% 0.60 [-0.23, 1.43]
Lyketsos 2003 -1.4 10.0885 24 0.5 9.145 20 0.6% -1.90 [-7.59, 3.79]
Subtotal (95% CI) 213 180 23.3% 0.28 [-0.54, 1.09]
Heterogeneity: Tau² = 0.05; Chi² = 2.13, df = 2 (P = 0.34); I² = 6%
Test for overall effect: Z = 0.66 (P = 0.51)
1.7.3 mirtazapine
Banerjee 2011* -1.71 4.2078 76 0 4.2078 41 6.7% -1.71 [-3.31, -0.11]
Banerjee 2021 4.6 9.5275 23 -0.5 9.5807 27 0.7% 5.10 [-0.21, 10.41]
Subtotal (95% CI) 99 68 7.4% 1.20 [-5.40, 7.81]
Heterogeneity: Tau² = 19.18; Chi² = 5.79, df = 1 (P = 0.02); I² = 83%
Test for overall effect: Z = 0.36 (P = 0.72)
1.7.4 citalopram
Porsteinsson 2014 -0.17 6.8353 94 0.93 7.4845 92 4.3% -1.10 [-3.16, 0.96]
Zhou 2019 0.67 0.772 39 0.18 0.644 39 29.3% 0.49 [0.17, 0.81]
Subtotal (95% CI) 133 131 33.6% 0.03 [-1.37, 1.44]
Heterogeneity: Tau² = 0.70; Chi² = 2.23, df = 1 (P = 0.14); I² = 55%
Test for overall effect: Z = 0.05 (P = 0.96)
1.7.5 vortioxetine
Jeong 2022* 0.59 1.0498 49 0 1.0498 51 26.7% 0.59 [0.18, 1.00]
Subtotal (95% CI) 49 51 26.7% 0.59 [0.18, 1.00]
Heterogeneity: Not applicable
Test for overall effect: Z = 2.81 (P = 0.005)
1.7.6 bupropion
Maier 2020 -0.05 4.14 54 0.4 4.0667 54 7.0% -0.45 [-2.00, 1.10]
Subtotal (95% CI) 54 54 7.0% -0.45 [-2.00, 1.10]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 575 517 100.0% 0.21 [-0.25, 0.67]
Heterogeneity: Tau² = 0.16; Chi² = 16.27, df = 9 (P = 0.06); I² = 45%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi² = 2.40, df = 5 (P = 0.79), I² = 0%
-10 -5 0 5 10
Favours [PL] Favours [AD]

MMSE - stratified by drug



ADAS-Cog



DEM-QoL



DEM-QoL - stratified by drug



CMAI



BEHAVE-AD



NBRS



ANTIPSYCHOTICS

CMAI



CMAI – stratified by drug



NPI


antipsychotic
PL
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
5.17.1 aripiprazole
De Deyn 2005 -11.2 23.65 103 -9.75 23.5 100 15.4% -1.45 [-7.94, 5.04]
Mintzer 2007-10mg -17.6 16.6 121 -13 16.4 39 18.4% -4.60 [-10.54, 1.34]
Mintzer 2007-2mg -14.1 19.3 116 -13 16.4 39 16.7% -1.10 [-7.33, 5.13]
Mintzer 2007-5mg -15.9 18.2 120 -13 16.4 39 17.5% -2.90 [-8.99, 3.19]
Streim 2008 -16.43 17.32 128 -10.01 18.83 121 32.0% -6.42 [-10.92, -1.92]
Subtotal (95% CI) 588 338 100.0% -3.82 [-6.36, -1.27]
Heterogeneity: Tau² = 0.00; Chi² = 2.68, df = 4 (P = 0.61); I² = 0%
Test for overall effect: Z = 2.94 (P = 0.003)
5.17.2 olanzapine
Deberdt 2005 -11.8 22.8 193 -12.3 22 90 24.8% 0.50 [-5.07, 6.07]
De Deyn 2004-1.0mg -14.8 16.2 128 -13.7 20.3 32 13.4% -1.10 [-8.67, 6.47]
De Deyn 2004-2.5mg -15.7 14.9 134 -13.7 20.3 32 13.8% -2.00 [-9.47, 5.47]
De Deyn 2004-5.0mg -16.3 17 123 -13.7 20.3 33 13.5% -2.60 [-10.15, 4.95]
De Deyn 2004-7.5mg -17.7 15.7 128 -13.7 20.3 32 13.5% -4.00 [-11.54, 3.54]
Schneider 2006 -14 18.7 40 -9 20.6 47 11.2% -5.00 [-13.26, 3.26]
Street 2000-10mg -14 21.7 49 -10.4 27.5 15 3.3% -3.60 [-18.79, 11.59]
Street 2000-15mg -9.7 26.1 51 -10.4 27.5 15 3.1% 0.70 [-14.95, 16.35]
Street 2000-5mg -18.7 21.3 55 -10.4 27.5 15 3.4% -8.30 [-23.31, 6.71]
Subtotal (95% CI) 901 311 100.0% -2.13 [-4.90, 0.64]
Heterogeneity: Tau² = 0.00; Chi² = 2.45, df = 8 (P = 0.96); I² = 0%
Test for overall effect: Z = 1.51 (P = 0.13)
5.17.3 pimavanserin
Ballard 2018* -5.12 18.5674 90 0 18.5674 91 100.0% -5.12 [-10.53, 0.29]
Subtotal (95% CI) 90 91 100.0% -5.12 [-10.53, 0.29]
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
5.17.4 quetiapine
Kurlan 2007 -1 16.04 19 -1 20.55 18 7.8% 0.00 [-11.92, 11.92]
Paleacu 2008 -24.58 21.16 19 -19.42 19.02 19 6.8% -5.16 [-17.95, 7.63]
Schneider 2006 -16.6 18.3 31 -9 20.6 47 14.6% -7.60 [-16.33, 1.13]
Tariot 2006 -14.24 19.52 86 -9.68 19.01 94 35.0% -4.56 [-10.20, 1.08]
Zhong 2007-100mg -8.9 23.0043 120 -8.2 23.02 46 18.2% -0.70 [-8.52, 7.12]
Zhong 2007-200mg -9.7 23.4896 114 -8.2 23.02 46 17.7% -1.50 [-9.43, 6.43]
Subtotal (95% CI) 389 270 100.0% -3.45 [-6.78, -0.11]
Heterogeneity: Tau² = 0.00; Chi² = 2.11, df = 5 (P = 0.83); I² = 0%
Test for overall effect: Z = 2.03 (P = 0.04)
5.17.5 risperidone
Deberdt 2005 -9.7 19.5 190 -12.3 22 90 54.3% 2.60 [-2.72, 7.92]
Schneider 2006 -16.4 15 32 -9 20.6 47 45.7% -7.40 [-15.25, 0.45]
Subtotal (95% CI) 222 137 100.0% -1.97 [-11.73, 7.80]
Heterogeneity: Tau² = 38.28; Chi² = 4.27, df = 1 (P = 0.04); I² = 77%
Test for overall effect: Z = 0.39 (P = 0.69)
5.17.6 brexpiprazolo
Lee 2023 -17.3 13.1966 215 -12.7 12.6428 111 100.0% -4.60 [-7.54, -1.66]
Subtotal (95% CI) 215 111 100.0% -4.60 [-7.54, -1.66]
Heterogeneity: Not applicable
Test for overall effect: Z = 3.07 (P = 0.002)
-20
-10
0
10
20
Favours [experimental]
Favours [control]

NPI - stratified by drug



NPI-Ag



BPRS


antipsychotic
PL
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI
IV, Random, 95% CI
5.18.1 aripiprazole
De Deyn 2005 -8.53 12.3 100 -6.58 12.38 95 28.0% -1.95 [-5.42, 1.52]
Streim 2008 -7.73 8.16 123 -5.14 8.88 117 72.0% -2.59 [-4.75, -0.43]
Subtotal (95% CI) 223 212 100.0% -2.41 [-4.24, -0.58]
Heterogeneity: Tau² = 0.00; Chi² = 0.09, df = 1 (P = 0.76); I² = 0%
Test for overall effect: Z = 2.58 (P = 0.010)
5.18.2 olanzapine
Deberdt 2005 -3.5 10.4 182 -3.7 9.3 84 33.8% 0.20 [-2.30, 2.70]
De Deyn 2004-1.0mg -6.3 9.1 111 -6.9 11.9 31 10.3% 0.60 [-3.92, 5.12]
De Deyn 2004-2.5mg -8.7 9 129 -6.9 11.9 31 10.6% -1.80 [-6.27, 2.67]
De Deyn 2004-5.0mg -6.4 9.5 113 -6.9 11.9 32 10.5% 0.50 [-3.98, 4.98]
De Deyn 2004-7.5mg -9.5 9.6 117 -6.9 11.9 31 10.3% -2.60 [-7.14, 1.94]
Schneider 2006 -7.4 9.8 40 -3.9 9.8 48 12.5% -3.50 [-7.61, 0.61]
Street 2000-10mg -5.6 10 37 -1.4 11.1 11 4.0% -4.20 [-11.51, 3.11]
Street 2000-15mg -4 10.9 39 -1.4 11.1 11 3.9% -2.60 [-10.00, 4.80]
Street 2000-5mg -6.8 8.6 40 -1.4 11.1 11 4.2% -5.40 [-12.48, 1.68]
Subtotal (95% CI) 808 290 100.0% -1.20 [-2.66, 0.25]
Heterogeneity: Tau² = 0.00; Chi² = 6.14, df = 8 (P = 0.63); I² = 0%
Test for overall effect: Z = 1.63 (P = 0.10)
5.18.3 quetiapine
Schneider 2006 -7.4 9.8 30 -3.9 9.8 48 32.3% -3.50 [-7.97, 0.97]
Tariot 2006 -9.06 11.07 85 -6.74 9.88 94 67.7% -2.32 [-5.41, 0.77]
Subtotal (95% CI) 115 142 100.0% -2.70 [-5.24, -0.16]
Heterogeneity: Tau² = 0.00; Chi² = 0.18, df = 1 (P = 0.67); I² = 0%
Test for overall effect: Z = 2.08 (P = 0.04)
5.18.4 risperidone
Deberdt 2005 -3.1 9.5 183 -3.7 9.3 84 59.5% 0.60 [-1.82, 3.02]
Schneider 2006 -8.5 12.2 32 -3.9 9.8 48 40.5% -4.60 [-9.66, 0.46]
Subtotal (95% CI) 215 132 100.0% -1.51 [-6.51, 3.50]
Heterogeneity: Tau² = 9.43; Chi² = 3.31, df = 1 (P = 0.07); I² = 70%
Test for overall effect: Z = 0.59 (P = 0.56)
-10 -5 0 5 10
Favours [AP] Favours [PL]

BPRS - stratified by drug



Adverse events



Adverse events - extrapyramidal



Adverse events – drowsiness



Adverse events – cerebrovascular



Serious adverse events



Mortality


antipsychotic PL Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI
5.15.1 aripiprazole
De Deyn 2005 4 106 0 102 1.5% 8.66 [0.47, 158.91]
Mintzer 2007 15 366 3 121 8.7% 1.65 [0.49, 5.61]
Streim 2008 3 131 3 125 5.2% 0.95 [0.20, 4.64]
Subtotal (95% CI) 603 348 15.5% 1.62 [0.65, 4.06]
Total events 22 6
Heterogeneity: Tau² = 0.00; Chi² = 1.77, df = 2 (P = 0.41); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)
5.15.2 olanzapine
Deberdt 2005 6 204 0 47 1.6% 3.04 [0.17, 53.11]
De Deyn 2004 15 520 2 129 6.1% 1.86 [0.43, 8.03]
Schneider 2006 1 100 1 46 1.7% 0.46 [0.03, 7.19]
Street 2000 6 159 0 47 1.6% 3.90 [0.22, 67.98]
Subtotal (95% CI) 983 269 11.0% 1.79 [0.60, 5.31]
Total events 28 3
Heterogeneity: Tau² = 0.00; Chi² = 1.39, df = 3 (P = 0.71); I² = 0%
Test for overall effect: Z = 1.05 (P = 0.30)
5.15.3 quetiapine
Ballard 2005 1 31 0 31 1.3% 3.00 [0.13, 70.92]
Schneider 2006 3 94 1 46 2.6% 1.47 [0.16, 13.73]
Tariot 2006 4 124 4 125 7.0% 1.01 [0.26, 3.94]
Zhong 2007 16 241 3 92 8.9% 2.04 [0.61, 6.82]
Subtotal (95% CI) 490 294 19.9% 1.56 [0.69, 3.51]
Total events 24 8
Heterogeneity: Tau² = 0.00; Chi² = 0.75, df = 3 (P = 0.86); I² = 0%
Test for overall effect: Z = 1.08 (P = 0.28)
5.15.4 risperidone
Brodaty 2003 6 167 4 170 8.4% 1.53 [0.44, 5.31]
Deberdt 2005 4 196 0 47 1.5% 2.19 [0.12, 40.04]
De Deyn 1999 1 115 5 114 2.9% 0.20 [0.02, 1.67]
Katz 1999 25 462 5 163 14.7% 1.76 [0.69, 4.53]
Mintzer 2006 9 235 6 238 12.6% 1.52 [0.55, 4.20]
Schneider 2006 1 85 1 47 1.7% 0.55 [0.04, 8.64]
Subtotal (95% CI) 1260 779 41.9% 1.35 [0.77, 2.37]
Total events 46 21
Heterogeneity: Tau² = 0.00; Chi² = 4.05, df = 5 (P = 0.54); I² = 0%
Test for overall effect: Z = 1.06 (P = 0.29)
5.15.5 pimavanserin
Ballard 2018 4 90 4 91 7.1% 1.01 [0.26, 3.92]
Subtotal (95% CI) 90 91 7.1% 1.01 [0.26, 3.92]
Total events 4 4
Heterogeneity: Not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
5.15.6 brexpiprazole
Grossberg 2020-f 1 133 1 137 1.7% 1.03 [0.07, 16.30]
Grossberg 2020-s 5 297 0 136 1.6% 5.06 [0.28, 90.81]
Lee 2023 1 226 0 116 1.3% 1.55 [0.06, 37.66]
Subtotal (95% CI) 656 389 4.6% 1.99 [0.37, 10.83]
Total events 7 1
Heterogeneity: Tau² = 0.00; Chi² = 0.68, df = 2 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 4082 2170 100.0% 1.47 [1.03, 2.11]
Total events 131 43
Heterogeneity: Tau² = 0.00; Chi² = 9.21, df = 20 (P = 0.98); I² = 0%
Test for overall effect: Z = 2.10 (P = 0.04)
Test for subgroup differences: Chi² = 0.69, df = 5 (P = 0.98), I² = 0%
0.01 0.1 1 10 100
Favours [experimental] Favours [control]

ANTIPSYCHOTIC SUSPENSION

Behavioral symptoms worsening

Study or Subgroup	withdrawal Events	Total	continuation Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
Ballard 2004	2	22	0	14	1.1%	3.26 [0.17, 63.30]
Bridges-Parlet 1997	4	17	3	16	5.2%	1.25 [0.33, 4.76]
Devenand 2011	4	15	2	15	3.9%	2.00 [0.43, 9.32]
Devenant 2012	12	36	11	46	19.3%	1.39 [0.70, 2.79]
Ruths 2004	9	27	4	28	8.3%	2.33 [0.81, 6.68]
Ruths 2008	8	10	4	10	13.7%	2.00 [0.88, 4.54]
van Reekum 2002	23	40	22	70	48.5%	1.83 [1.18, 2.83]
Total (95% CI)		**167**		**199**	**100.0%**	**1.78 [1.31, 2.41]**
Total events	62		46			

Heterogeneity: Tau² = 0.00; Chi² = 1.27, df = 6 (P = 0.97); I² = 0%
Test for overall effect: Z = 3.70 (P = 0.0002)



Behavioral symptoms severity

Study or Subgroup	withdrawal Mean	SD	Total	continuation Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI
Ballard 2004	-1.3	9.4	46	0.2	12	54	39.5%	-0.14 [-0.53, 0.26]
Ballard 2008	11.4	17.7	31	1.4	22.1	28	30.6%	0.50 [-0.02, 1.02]
Ruths 2008	-0.19	5.3	27	-1.79	4.9	28	29.8%	0.31 [-0.22, 0.84]
Total (95% CI)			**104**			**110**	**100.0%**	**0.19 [-0.20, 0.58]**

Heterogeneity: Tau² = 0.06; Chi² = 4.08, df = 2 (P = 0.13); I² = 51%
Test for overall effect: Z = 0.94 (P = 0.35)



Mortality

Study or Subgroup	withdrawal Events	Total	continuation Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
Ballard 2004	0	22	0	14		Not estimable
Ballard 2008	1	17	2	16	5.1%	0.47 [0.05, 4.70]
Bridges-Parlet 1997	3	46	3	54	11.3%	1.17 [0.25, 5.54]
Devenant 2012	15	64	19	64	80.0%	0.79 [0.44, 1.41]
van Reekum 2002	1	40	1	70	3.6%	1.75 [0.11, 27.22]
Total (95% CI)		**189**		**218**	**100.0%**	**0.83 [0.49, 1.39]**
Total events	20		25			

Heterogeneity: Tau² = 0.00; Chi² = 0.74, df = 3 (P = 0.86); I² = 0%
Test for overall effect: Z = 0.71 (P = 0.48)



MELATONIN

Average of total night-time sleep time



Ratio between daytime and night-time sleep time



GINKGO BILOBA

NPI



ADL



Quality of life



AChEI/MEMANTINE

ADAS-Cog



ADL



NPI



METHYLPHENIDATE

AES



NPI



MMSE



Serious adverse events



MOOD STABILIZERS

BPRS



Adverse events



CMAI

Study or Subgroup	mood stabilizers Mean	SD	Total	PL Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
13.1.1 valproate								
Herrmann 2007	10.38	16.74	14	-5	17.44	13	25.2%	15.38 [2.47, 28.29]
Porsteinsson 2001	-9.5	22.2	28	-7.3	12.3	28	32.4%	-2.20 [-11.60, 7.20]
Tariot 2005	-6.7	15.6	72	-3.5	14.5	75	42.3%	-3.20 [-8.07, 1.67]
Subtotal (95% CI)			**114**			**116**	**100.0%**	**1.81 [-7.64, 11.27]**

Heterogeneity: Tau² = 48.74; Chi² = 7.02, df = 2 (P = 0.03); I² = 72%
Test for overall effect: Z = 0.38 (P = 0.71)



NPI

Study or Subgroup	mood stabilizers Mean	SD	Total	PL Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
13.2.1 valproate								
Herrmann 2007	12.5	18.39	14	-5.77	18.52	13	8.1%	18.27 [4.34, 32.20]
Profenno 2005-1.5g	1.38	2	8	-1	2	2	47.6%	2.38 [-0.72, 5.48]
Profenno 2005-1g	2.25	3.15	8	-1	2	2	44.3%	3.25 [-0.28, 6.78]
Subtotal (95% CI)			**30**			**17**	**100.0%**	**4.05 [-0.19, 8.29]**

Heterogeneity: Tau² = 7.32; Chi² = 4.76, df = 2 (P = 0.09); I² = 58%
Test for overall effect: Z = 1.87 (P = 0.06)



MMSE

Study or Subgroup	mood stabilizers Mean	SD	Total	PL Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
13.4.1 valproate								
Herrmann 2007	-0.17	5.31	12	-0.23	4.11	13	5.3%	0.06 [-3.68, 3.80]
Porsteinsson 2001	-1.8	5.6	28	-1.6	6.3	28	7.7%	-0.20 [-3.32, 2.92]
Profenno 2005-1.5g	-2.88	2.47	8	1.25	2.5	2	5.0%	-4.13 [-7.99, -0.27]
Profenno 2005-1g	0.63	5.88	8	1.25	2.5	2	2.6%	-0.62 [-5.97, 4.73]
Tariot 2005	-0.85	2.8	72	0.14	3.2	75	79.4%	-0.99 [-1.96, -0.02]
Subtotal (95% CI)			**128**			**120**	**100.0%**	**-1.02 [-1.89, -0.16]**

Heterogeneity: Tau² = 0.00; Chi² = 3.10, df = 4 (P = 0.54); I² = 0%
Test for overall effect: Z = 2.31 (P = 0.02)

13.4.2 carbamazepina								
Olin 2001	-0.1	2.7	9	-0.5	2.9	12	100.0%	0.40 [-2.01, 2.81]
Subtotal (95% CI)			**9**			**12**	**100.0%**	**0.40 [-2.01, 2.81]**

Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)



PSMS


mood stabilizers
PL
Mean Difference
Mean Difference
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI
IV, Fixed, 95% CI
13.5.1 valproate
Porsteinsson 2001 0.4 2.6 28 -0.2 2.2 28 39.2% 0.60 [-0.66, 1.86]
Tariot 2005 1.03 3.5 72 0.16 2.7 75 60.8% 0.87 [-0.14, 1.88]
Subtotal (95% CI) 100 103 100.0% 0.76 [-0.03, 1.55]
Heterogeneity: Chi² = 0.11, df = 1 (P = 0.74); I² = 0%
Test for overall effect: Z = 1.90 (P = 0.06)
13.5.2 carbamazepine
Olin 2001 -0.5 1.6 9 -0.6 1.6 12 100.0% 0.10 [-1.28, 1.48]
Subtotal (95% CI) 9 12 100.0% 0.10 [-1.28, 1.48]
Heterogeneity: Not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
-2
-1
0
1
2
Favours [experimental]
Favours [control]

REVIEW QUESTION 21b. What are the most effective non-pharmacological interventions for managing illness emergent non-cognitive symptoms, such as psychosis, depression, behavioral changes in people living with dementia?

AROMATHERAPY (lavender)

CMAI



NPI



RECREATIONAL ACTIVITIES

ABMI



LIGHT THERAPY

CMAI



NPI



SLEEP INTERVENTIONS

Multicomponent interventions including improving sleep hygiene, exposure to light, and physical activity

Total night-time sleep time



Interventions based on exposure to bright light and controlled light

Total night-time sleep time



Total day-time sleep time



PSYCHOLOGICAL INTERVENTIONS

Cognitive Behavioral Therapy for the treatment of psychological and behavioral disorders

MMSE



CSDD



RAID



QoL-AD



MUSIC THERAPY

CMAI



GDS



NPI



MMSE



ADL



ROBOT THERAPY

interactive robot with the appearance of a baby seal – CMAI-SF



interactive robot with the appearance of a baby seal – CSDD



interactive robot with the appearance of a baby seal – RAID



TRANSCRANIAL STIMULATION

ADL



TAILORED ACTIVITY PROGRAM

NPI-Ag



NPI-aggressività



NPI-ansia



DOLL THERAPY

NPI



REVIEW QUESTION 22b. Are there effective methods for treating intercurrent illness in people living with dementia that are different from those already in use for people who do not have dementia?

HIP FRACTURE REHABILITATION

Intervention to enhance inpatient and home care compared with standard care

In-hospital mortality



Mortality at 12 months



Implementation of inpatient care management coordinated by a geriatrician vs coordinated by an orthopedist

Incidence of delirium during hospitalization



PHYSICAL EXERCISE FOR FALL PREVENTION

Fall risk



Hip fracture risk



PHYSICAL EXERCISE-BASED REHABILITATION AT HOME VS STANDARD CARE

Number of falls



REVIEW QUESTION 24. What models of palliative care are effective for people with dementia?

MULTIDIMENSIONAL AND MULTIDISCIPLINARY END-OF-LIFE EDUCATION INTERVENTIONS

FPCS